登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07640789,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
In platinum-based radical chemoradiotherapy, patients must have received a total radiation dose of 60 Gy ± 10% before randomization;
入选标准第 8 条
Toxicities from prior chemoradiotherapy must have resolved to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
入选标准第 9 条
Prior treatment with ADC drugs using topoisomerase I inhibitors as toxins, or antibodies/ADCs targeting EGFR and/or HER3;
排除标准第 4 条
ECOG performance status score of 0 or 1;
入选标准第 10 条
Diagnosis of active malignancy within 5 years prior to study randomization;
排除标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07640789,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and comply with the protocol requirements; Age ≥ 18 years and ≤ 75 years, regardless of gender; Expected survival time ≥ 3 months; Unresectable Stage III non-small cell lung cancer; Detection of one of the EGFR-sensitive mutation types in tumor tissue; Agree to provide archived primary tumor tissue specimens or fresh tissue samples within 1 year; In platinum-based radical chemoradiotherapy, the platinum-containing chemotherapy regimen must include one of the specified drugs in addition to the platinum agent; In platinum-based radical chemoradiotherapy, patients must have received a total radiation dose of 60 Gy ± 10% before randomization; Toxicities from prior chemoradiotherapy must have resolved to ≤ Grade 1 as defined by NCI-CTCAE v6.0; ECOG performance status score of 0 or 1; No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%; Organ function levels must meet the requirements; Urine protein ≤ 1+ or < 1000 mg/24h; For premenopausal women with childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the test must rule out pregnancy; they must not be lactating; all enrolled trial participants must take adequate barrier contraceptive measures throughout the treatment period and for 7 months after treatment ends.排除标准:Exclusion Criteria:
SCLC, mixed SCLC and NSCLC, or other non-NSCLC pathological types; The trial participant has received other chemotherapy, radiotherapy, etc., for NSCLC apart from radical chemoradiotherapy; Major surgery within 4 weeks prior to the first dose; Prior treatment with ADC drugs using topoisomerase I inhibitors as toxins, or antibodies/ADCs targeting EGFR and/or HER3; History of severe heart disease or cerebrovascular disease; Prolonged QTc interval, complete left bundle branch block, second- or third-degree atrioventricular block, or frequent and uncontrolled arrhythmias; Any thrombotic events such as deep vein thrombosis, arterial thrombosis, or pulmonary embolism within 6 months prior to screening; Diagnosis of active malignancy within 5 years prior to study randomization; Hypertension poorly controlled by two antihypertensive medications; Trial participants with poorly controlled blood glucose levels; Current radiation pneumonitis of Grade ≥2 as defined by CTCAE; Concurrent lung disease resulting in clinically severe respiratory impairment; Severe infection within 4 weeks prior to study randomization; Large serous cavity effusions or symptomatic serous cavity effusions; Imaging findings suggesting tumor invasion or encasement of major blood vessels in the abdomen, chest, neck, or pharynx; Severe non-healing wounds, ulcers, or fractures within 4 weeks prior to signing informed consent; Trial participants with clinically significant bleeding or a clear tendency for bleeding within 4 weeks prior to signing informed consent; Trial participants with a history of inflammatory bowel disease, extensive bowel resection, or immune-mediated enteritis; History of allergy to recombinant humanized antibodies or chimeric human-mouse antibodies, or allergy to any excipient components of the investigational drug; History of autologous or allogeneic stem cell transplantation; Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection; History of severe neurological or psychiatric disorders, or a history of substance abuse, alcoholism, or drug addiction; Trial participants planning to receive or having received live vaccines within 28 days prior to study randomization; Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other reasons.
引自 ClinicalTrials.gov, NCT07640789, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07640789,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。